Quanterix
Open
$3.14
Prev. Close
$3.14
High
$3.14
Low
$3.12
Market Snapshot
$142.47M
-1.3
-1.00
$137.42M
450
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 450 full-time employees. The company went IPO on 2017-12-07. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
emptyResult
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 450 full-time employees. The company went IPO on 2017-12-07. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
Recently from Cashu
Quanterix Reports Earnings, Highlights Innovations in Biomarker Detection and Alzheimer’s Diagnostics
Quanterix Advances Diagnostics with Innovative Biomarker Detection Technology Quanterix Corp. underscores its significant strides in biomarker detection technology as it announces its recent fourth-qu…
Quanterix Reports Revenue Growth and Advances Biomarker Detection in Strategic Initiatives
Quanterix Advances in Biomarker Detection Amid Strategic Growth Initiatives Quanterix, a frontrunner in the field of biomarker detection technology, records a notable surge in its fourth-quarter earni…
Quanterix Earnings Announcement: Spotlight on Simoa Technology and Future Growth in Diagnostics
Quanterix Poised for Earnings Reveal: Focus on Innovation in Digital Immunoassays Quanterix, a leading innovator in the realm of digital immunoassays, prepares to announce its quarterly earnings on Ma…
Quanterix Prepares for Earnings Call Amid Innovations in Diagnostic Technology
Quanterix Gears Up for Earnings Announcement Amid Breakthroughs in Diagnostics Technology Quanterix, a leader in the field of digital immunoassays, prepares to announce its quarterly earnings on March…